Portola Pharmaceuticals, Inc. stock price

Portola Pharmaceuticals, Inc. latest news:


  • 12/26/2017 13:33:00

    Here's Why Portola Pharmaceuticals Inc. Tanked as Much as 10%

    This isn't the sort of update that shareholders were looking for.

  • 12/22/2017 17:40:41

    Portola Pharma stock falls 7% after delay in FDA review

    Portola Pharmaceuticals Inc. stock fell 7% in late trading Friday afternoon after the company said a regulatory review of a proposed drug would be extended. The Food and Drug Administration asked Portola for more data on a study of the biologic drug, AndexXa, which will extend the time allowed for the review by 90 days. Portola said that the review period will now end May 4, 2018, instead of Feb. 3. AndexXa is being developed as an antidote for anticoagulant drugs, which can lead to uncontrolled bleeding. Portola shares declined to about $51 in after-hours trading, after closing Friday at $54.86.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/22/2017 15:25:37

    BRIEF-Portola Pharma Says FDA will extend review of AndexXa by 90 days

    * PORTOLA PHARMACEUTICALS PROVIDES UPDATE ON BIOLOGICS LICENSE APPLICATION (BLA) FOR ANDEXXA® (ANDEXANET ALFA)

  • 12/19/2017 09:13:09

    BRIEF-U.S. FDA Approves Prior Approval Supplement For Launch Of Portola Pharmaceuticals' Betrixaban

    Portola Pharmaceuticals Inc(PTLA): * U.S. FOOD AND DRUG ADMINISTRATION APPROVES PRIOR APPROVAL SUPPLEMENT FOR COMMERCIAL LAUNCH OF PORTOLA PHARMACEUTICALS’ NOVEL ORAL ANTICOAGULANT BEVYXXA®. * Portola Pharmaceuticals Inc (PTLA) - CO PLANS TO INITIATE COMMERCIAL LAUNCH IN EARLY JANUARY 2018 Source text for Eikon: Further company coverage:

  • 11/21/2017 16:50:14

    Portola shares slip as FDA review pushes possible drug release to February

    Portola Pharmaceuticals Inc. shares declined in the extended session Tuesday after the drug maker said the Food and Drug Administration needs more time to review company manufacturing changes to a drug already approved. Portola shares declined 3.5% to $49.01 after hours. Portola said the FDA needs time to review the entire Prior Approval Supplement submission for Bevyxxa, approved to treat venous thromboembolism patients in June. The review time pushes out the release of Bevyxxa to February, given that the FDA is required to act by Jan. 30.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/21/2017 16:26:09

    BRIEF-Portola Pharmaceuticals provides update on Bevyxxa commercial launch

    * Portola Pharmaceuticals provides update on Bevyxxa(betrixaban) commercial launch

  • More trends:

    Potbelly CorporationPBPB | Potlatch CorporationPCH | Powell Industries, Inc.POWL | Power Integrations, Inc.POWI | Power Solutions International, Inc.PSIX | PowerShares DB Optimum Yield Diversified CommodityPDBC | PowerShares FTSE RAFI US 1500 Small-Mid PortfolioPRFZ | PowerShares Global Agriculture PortfolioPAGG | PowerShares Global Gold & Precious Metals PortfoliPSAU | PowerShares International BuyBack Achievers PortfoIPKW |